Smith Asset Management Group LP raised its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 74.2% during the 4th quarter, Holdings Channel reports. The firm owned 14,980 shares of the company’s stock after acquiring an additional 6,380 shares during the period. Smith Asset Management Group LP’s holdings in USANA Health Sciences were worth $1,764,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in USNA. Matarin Capital Management LLC purchased a new position in USANA Health Sciences in the third quarter valued at approximately $18,159,000. Vanguard Group Inc increased its stake in USANA Health Sciences by 10.7% in the third quarter. Vanguard Group Inc now owns 1,245,807 shares of the company’s stock valued at $150,182,000 after purchasing an additional 120,709 shares during the last quarter. Vanguard Group Inc. increased its stake in USANA Health Sciences by 10.7% in the third quarter. Vanguard Group Inc. now owns 1,245,807 shares of the company’s stock valued at $150,182,000 after purchasing an additional 120,709 shares during the last quarter. BlackRock Inc. increased its stake in USANA Health Sciences by 11.8% in the third quarter. BlackRock Inc. now owns 1,076,327 shares of the company’s stock valued at $129,750,000 after purchasing an additional 113,961 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in USANA Health Sciences by 53.2% in the third quarter. Robeco Institutional Asset Management B.V. now owns 241,011 shares of the company’s stock valued at $29,053,000 after purchasing an additional 83,672 shares during the last quarter. Institutional investors own 53.99% of the company’s stock.
Shares of USNA opened at $105.04 on Friday. The company has a market cap of $2.52 billion, a PE ratio of 20.36 and a beta of 0.53. USANA Health Sciences, Inc. has a 12-month low of $75.20 and a 12-month high of $137.95.
USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 5th. The company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.33 by ($0.01). The business had revenue of $299.02 million for the quarter, compared to analysts’ expectations of $305.79 million. USANA Health Sciences had a return on equity of 29.94% and a net margin of 10.61%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $1.11 earnings per share. As a group, research analysts predict that USANA Health Sciences, Inc. will post 5.4 EPS for the current year.
USANA Health Sciences declared that its Board of Directors has initiated a share repurchase program on Tuesday, October 23rd that allows the company to buyback $150.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 5.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
USNA has been the topic of several recent analyst reports. ValuEngine lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 8th. Pivotal Research upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating and set a $135.00 price target on the stock in a research note on Wednesday, October 24th. Finally, Sidoti upgraded shares of USANA Health Sciences from a “neutral” rating to a “buy” rating in a research note on Thursday, October 25th.
In other news, Director Myron W. Wentz sold 20,645 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $115.36, for a total transaction of $2,381,607.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Global Ltd Gull sold 12,436 shares of the firm’s stock in a transaction that occurred on Saturday, December 1st. The stock was sold at an average price of $70.45, for a total transaction of $876,116.20. Following the transaction, the insider now owns 10,921,009 shares in the company, valued at $769,385,084.05. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 19,117 shares of company stock worth $1,349,965 and have sold 178,861 shares worth $20,032,300. Company insiders own 48.00% of the company’s stock.
USANA Health Sciences Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Further Reading: Trading Strategy Methods and Types
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.